Literature DB >> 20199509

Low-dose rituximab for posttransplant recurrent membranous nephropathy.

P Cravedi, P Ruggenenti, G Remuzzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20199509     DOI： 10.1111/j.1600-6143.2010.03029.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN： 1600-6135            Impact factor:   8.086


× No keyword cloud information.
  4 in total

Review 1.  Recent progress in the pathophysiology and treatment of FSGS recurrence.

Authors:  P Cravedi; J B Kopp; G Remuzzi
Journal:  Am J Transplant       Date:  2013-01-11       Impact factor: 8.086

Review 2.  Recurrence of primary glomerulonephritis: Review of the current evidence.

Authors:  Fedaey Abbas; Mohsen El Kossi; Jon Kim Jin; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2017-12-24

3.  Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome.

Authors:  Annalisa Perna; Barbara Ruggiero; Manuel Alfredo Podestà; Luca Perico; Silvia Orisio; Hanna Debiec; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

Review 4.  FSGS Recurrence in Adults after Renal Transplantation.

Authors:  Michael Rudnicki
Journal:  Biomed Res Int       Date:  2016-04-10       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.